Global Surgical Hemostatic Agents 麻豆原创 Research Report 2024

Publication ID:

PB506246241

Publication Date:

June 7, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Hemostasis, also known as hemorrhage prevention, is the process that stops blood from leaking into a blood vessel. Hemostasis happens when a clot develops at the location of the blood vessel injury, repairing it. This report mainly focuses on surgical hemostatic agents market.
The global Surgical Hemostatic Agents market was valued at US$ 3975 million in 2023 and is anticipated to reach US$ 5746.2 million by 2030, witnessing a CAGR of 5.8% during the forecast period 2024-2030.
According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
This report aims to provide a comprehensive presentation of the global market for Surgical Hemostatic Agents, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Surgical Hemostatic Agents.
Report Scope
The Surgical Hemostatic Agents market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Surgical Hemostatic Agents market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Surgical Hemostatic Agents manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
J&J
Baxter
BD
Gelita
Pfizer
B Braun
CSL Behring
Ferrosan Medical Devices
Advance Medical Solution
Medtronic
Z-Medica
Marine Polymer
Equimedical
CryoLife
Segment by Type
Gelation Hemostats
Combination Hemostats
Others
Segment by Application
Hospitals
Surgical Centers
Other
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Surgical Hemostatic Agents manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Surgical Hemostatic Agents in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Surgical Hemostatic Agents 麻豆原创 Overview
1.1 Product Overview and Scope of Surgical Hemostatic Agents
1.2 Surgical Hemostatic Agents Segment by Type
1.2.1 Global Surgical Hemostatic Agents 麻豆原创 Value Comparison by Type (2024-2030)
1.2.2 Gelation Hemostats
1.2.3 Combination Hemostats
1.2.4 Others
1.3 Surgical Hemostatic Agents Segment by Application
1.3.1 Global Surgical Hemostatic Agents 麻豆原创 Value by Application: (2024-2030)
1.3.2 Hospitals
1.3.3 Surgical Centers
1.3.4 Other
1.4 Global Surgical Hemostatic Agents 麻豆原创 Size Estimates and Forecasts
1.4.1 Global Surgical Hemostatic Agents Revenue 2019-2030
1.4.2 Global Surgical Hemostatic Agents Sales 2019-2030
1.4.3 Global Surgical Hemostatic Agents 麻豆原创 Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Surgical Hemostatic Agents 麻豆原创 Competition by Manufacturers
2.1 Global Surgical Hemostatic Agents Sales 麻豆原创 Share by Manufacturers (2019-2024)
2.2 Global Surgical Hemostatic Agents Revenue 麻豆原创 Share by Manufacturers (2019-2024)
2.3 Global Surgical Hemostatic Agents Average Price by Manufacturers (2019-2024)
2.4 Global Surgical Hemostatic Agents Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Surgical Hemostatic Agents, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Surgical Hemostatic Agents, Product Type & Application
2.7 Surgical Hemostatic Agents 麻豆原创 Competitive Situation and Trends
2.7.1 Surgical Hemostatic Agents 麻豆原创 Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Surgical Hemostatic Agents Players 麻豆原创 Share by Revenue
2.7.3 Global Surgical Hemostatic Agents 麻豆原创 Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Surgical Hemostatic Agents Retrospective 麻豆原创 Scenario by Region
3.1 Global Surgical Hemostatic Agents 麻豆原创 Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Surgical Hemostatic Agents Global Surgical Hemostatic Agents Sales by Region: 2019-2030
3.2.1 Global Surgical Hemostatic Agents Sales by Region: 2019-2024
3.2.2 Global Surgical Hemostatic Agents Sales by Region: 2025-2030
3.3 Global Surgical Hemostatic Agents Global Surgical Hemostatic Agents Revenue by Region: 2019-2030
3.3.1 Global Surgical Hemostatic Agents Revenue by Region: 2019-2024
3.3.2 Global Surgical Hemostatic Agents Revenue by Region: 2025-2030
3.4 North America Surgical Hemostatic Agents 麻豆原创 Facts & Figures by Country
3.4.1 North America Surgical Hemostatic Agents 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Surgical Hemostatic Agents Sales by Country (2019-2030)
3.4.3 North America Surgical Hemostatic Agents Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Surgical Hemostatic Agents 麻豆原创 Facts & Figures by Country
3.5.1 Europe Surgical Hemostatic Agents 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Surgical Hemostatic Agents Sales by Country (2019-2030)
3.5.3 Europe Surgical Hemostatic Agents Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Surgical Hemostatic Agents 麻豆原创 Facts & Figures by Country
3.6.1 Asia Pacific Surgical Hemostatic Agents 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Surgical Hemostatic Agents Sales by Country (2019-2030)
3.6.3 Asia Pacific Surgical Hemostatic Agents Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Surgical Hemostatic Agents 麻豆原创 Facts & Figures by Country
3.7.1 Latin America Surgical Hemostatic Agents 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Surgical Hemostatic Agents Sales by Country (2019-2030)
3.7.3 Latin America Surgical Hemostatic Agents Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Surgical Hemostatic Agents 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa Surgical Hemostatic Agents 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Surgical Hemostatic Agents Sales by Country (2019-2030)
3.8.3 Middle East and Africa Surgical Hemostatic Agents Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Surgical Hemostatic Agents Sales by Type (2019-2030)
4.1.1 Global Surgical Hemostatic Agents Sales by Type (2019-2024)
4.1.2 Global Surgical Hemostatic Agents Sales by Type (2025-2030)
4.1.3 Global Surgical Hemostatic Agents Sales 麻豆原创 Share by Type (2019-2030)
4.2 Global Surgical Hemostatic Agents Revenue by Type (2019-2030)
4.2.1 Global Surgical Hemostatic Agents Revenue by Type (2019-2024)
4.2.2 Global Surgical Hemostatic Agents Revenue by Type (2025-2030)
4.2.3 Global Surgical Hemostatic Agents Revenue 麻豆原创 Share by Type (2019-2030)
4.3 Global Surgical Hemostatic Agents Price by Type (2019-2030)
5 Segment by Application
5.1 Global Surgical Hemostatic Agents Sales by Application (2019-2030)
5.1.1 Global Surgical Hemostatic Agents Sales by Application (2019-2024)
5.1.2 Global Surgical Hemostatic Agents Sales by Application (2025-2030)
5.1.3 Global Surgical Hemostatic Agents Sales 麻豆原创 Share by Application (2019-2030)
5.2 Global Surgical Hemostatic Agents Revenue by Application (2019-2030)
5.2.1 Global Surgical Hemostatic Agents Revenue by Application (2019-2024)
5.2.2 Global Surgical Hemostatic Agents Revenue by Application (2025-2030)
5.2.3 Global Surgical Hemostatic Agents Revenue 麻豆原创 Share by Application (2019-2030)
5.3 Global Surgical Hemostatic Agents Price by Application (2019-2030)
6 Key Companies Profiled
6.1 J&J
6.1.1 J&J Corporation Information
6.1.2 J&J Description and Business Overview
6.1.3 J&J Surgical Hemostatic Agents Sales, Revenue and Gross Margin (2019-2024)
6.1.4 J&J Surgical Hemostatic Agents Product Portfolio
6.1.5 J&J Recent Developments/Updates
6.2 Baxter
6.2.1 Baxter Corporation Information
6.2.2 Baxter Description and Business Overview
6.2.3 Baxter Surgical Hemostatic Agents Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Baxter Surgical Hemostatic Agents Product Portfolio
6.2.5 Baxter Recent Developments/Updates
6.3 BD
6.3.1 BD Corporation Information
6.3.2 BD Description and Business Overview
6.3.3 BD Surgical Hemostatic Agents Sales, Revenue and Gross Margin (2019-2024)
6.3.4 BD Surgical Hemostatic Agents Product Portfolio
6.3.5 BD Recent Developments/Updates
6.4 Gelita
6.4.1 Gelita Corporation Information
6.4.2 Gelita Description and Business Overview
6.4.3 Gelita Surgical Hemostatic Agents Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Gelita Surgical Hemostatic Agents Product Portfolio
6.4.5 Gelita Recent Developments/Updates
6.5 Pfizer
6.5.1 Pfizer Corporation Information
6.5.2 Pfizer Description and Business Overview
6.5.3 Pfizer Surgical Hemostatic Agents Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Pfizer Surgical Hemostatic Agents Product Portfolio
6.5.5 Pfizer Recent Developments/Updates
6.6 B Braun
6.6.1 B Braun Corporation Information
6.6.2 B Braun Description and Business Overview
6.6.3 B Braun Surgical Hemostatic Agents Sales, Revenue and Gross Margin (2019-2024)
6.6.4 B Braun Surgical Hemostatic Agents Product Portfolio
6.6.5 B Braun Recent Developments/Updates
6.7 CSL Behring
6.6.1 CSL Behring Corporation Information
6.6.2 CSL Behring Description and Business Overview
6.6.3 CSL Behring Surgical Hemostatic Agents Sales, Revenue and Gross Margin (2019-2024)
6.4.4 CSL Behring Surgical Hemostatic Agents Product Portfolio
6.7.5 CSL Behring Recent Developments/Updates
6.8 Ferrosan Medical Devices
6.8.1 Ferrosan Medical Devices Corporation Information
6.8.2 Ferrosan Medical Devices Description and Business Overview
6.8.3 Ferrosan Medical Devices Surgical Hemostatic Agents Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Ferrosan Medical Devices Surgical Hemostatic Agents Product Portfolio
6.8.5 Ferrosan Medical Devices Recent Developments/Updates
6.9 Advance Medical Solution
6.9.1 Advance Medical Solution Corporation Information
6.9.2 Advance Medical Solution Description and Business Overview
6.9.3 Advance Medical Solution Surgical Hemostatic Agents Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Advance Medical Solution Surgical Hemostatic Agents Product Portfolio
6.9.5 Advance Medical Solution Recent Developments/Updates
6.10 Medtronic
6.10.1 Medtronic Corporation Information
6.10.2 Medtronic Description and Business Overview
6.10.3 Medtronic Surgical Hemostatic Agents Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Medtronic Surgical Hemostatic Agents Product Portfolio
6.10.5 Medtronic Recent Developments/Updates
6.11 Z-Medica
6.11.1 Z-Medica Corporation Information
6.11.2 Z-Medica Surgical Hemostatic Agents Description and Business Overview
6.11.3 Z-Medica Surgical Hemostatic Agents Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Z-Medica Surgical Hemostatic Agents Product Portfolio
6.11.5 Z-Medica Recent Developments/Updates
6.12 Marine Polymer
6.12.1 Marine Polymer Corporation Information
6.12.2 Marine Polymer Surgical Hemostatic Agents Description and Business Overview
6.12.3 Marine Polymer Surgical Hemostatic Agents Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Marine Polymer Surgical Hemostatic Agents Product Portfolio
6.12.5 Marine Polymer Recent Developments/Updates
6.13 Equimedical
6.13.1 Equimedical Corporation Information
6.13.2 Equimedical Surgical Hemostatic Agents Description and Business Overview
6.13.3 Equimedical Surgical Hemostatic Agents Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Equimedical Surgical Hemostatic Agents Product Portfolio
6.13.5 Equimedical Recent Developments/Updates
6.14 CryoLife
6.14.1 CryoLife Corporation Information
6.14.2 CryoLife Surgical Hemostatic Agents Description and Business Overview
6.14.3 CryoLife Surgical Hemostatic Agents Sales, Revenue and Gross Margin (2019-2024)
6.14.4 CryoLife Surgical Hemostatic Agents Product Portfolio
6.14.5 CryoLife Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Surgical Hemostatic Agents Industry Chain Analysis
7.2 Surgical Hemostatic Agents Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Surgical Hemostatic Agents Production Mode & Process
7.4 Surgical Hemostatic Agents Sales and 麻豆原创ing
7.4.1 Surgical Hemostatic Agents Sales Channels
7.4.2 Surgical Hemostatic Agents Distributors
7.5 Surgical Hemostatic Agents Customers
8 Surgical Hemostatic Agents 麻豆原创 Dynamics
8.1 Surgical Hemostatic Agents Industry Trends
8.2 Surgical Hemostatic Agents 麻豆原创 Drivers
8.3 Surgical Hemostatic Agents 麻豆原创 Challenges
8.4 Surgical Hemostatic Agents 麻豆原创 Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

J&J
Baxter
BD
Gelita
Pfizer
B Braun
CSL Behring
Ferrosan Medical Devices
Advance Medical Solution
Medtronic
Z-Medica
Marine Polymer
Equimedical
CryoLife

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.